DelveInsight’s “Congenital Hyperinsulinism (CHI) – Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Congenital Hyperinsulinism, historical and forecasted epidemiology as well as the Congenital Hyperinsulinism market trends in the United States, the EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Key Highlights
Key Companies working on Congenital HyperInsulinism Disease include Zealand Pharma, Rezolute, Hanmi Pharmaceutical, Crinetics Pharmaceuticals, and many others.
Key Therapies included in the Congenital HyperInsulinism Disease market include HM15136, Dasiglucagon, Glucagon and many others
Congenital HyperInsulinism Overview
Congenital Hyperinsulinism is characterized by inappropriate and unregulated insulin secretion from the β cells of the pancreas. In CHI, the β cells release insulin inappropriately, and insulin secretion is not regulated by the blood glucose level (as occurs normally). The action of insulin causes hyperinsulinemic hypoglycemia. High insulin levels prevent the formation of ketone bodies, which means that the brain is deprived of its most important fuel (glucose), and ketone bodies are used as alternative fuels.
As Congenital HyperInsulinism is a congenital condition, a child shows symptoms within the first few days of life, although very occasionally, symptoms may appear later in infancy. Symptoms of hypoglycemia can include floppiness, shakiness, poor feeding, and sleepiness, all of which are due to low blood glucose levels. Seizures (fits or convulsions) can also occur due to low blood glucose levels. If the child’s blood glucose level is not corrected, it can lead to loss of consciousness and potential brain injury.
Congenital HyperInsulinism Disease Epidemiology Insights
In the year 2021, the total diagnosed prevalent cases of Congenital Hyperinsulinism were 15,487 in the 7MM which is expected to grow during the study period, i.e., 2019–2032.
Click here to learn more about the Congenital HyperInsulinism Disease Market Landscape
The Report Covers the Congenital Hyperinsulinism Disease Epidemiology Segmented by:
Congenital HyperInsulinism prevalent cases
Congenital HyperInsulinism incident cases
Congenital HyperInsulinism treatment cases
Congenital HyperInsulinism diagnosed cases
Congenital HyperInsulinism Disease Market Outlook
There is only one approved therapy for Congenital HyperInsulinism in the market, namely, PROGLYCEM (diazoxide) – a non-diuretic benzothiadiazine derivative used for the management of symptomatic hypoglycemia. Proglycem capsules and suspension are manufactured by IVAX Pharmaceuticals and Teva Pharmaceuticals, respectively; the suspension was manufactured for Gate Pharmaceuticals, a division of Teva Pharmaceuticals.
A number of children with Congenital HyperInsulinism are partially or completely unresponsive to diazoxide. Second-line treatment with other agents such as octreotide/lanreotide, is required in such children. Somatostatin receptor analogs (SSRAs), typically octreotide/lanreotide, which inhibit insulin release, are preferred as second-line treatment in diazoxide-unresponsive patients. The use of SSRAs is off-label as only diazoxide is approved for CHI. Octreotide reduces insulin release by decreasing the insulin gene promoter activity, inhibiting voltage-dependent calcium channels and adenylyl cyclase activity. Long‐acting SSRAs are favored by families on account of the monthly injection regimen without recourse to daily injections as needed for octreotide therapy. One problem with using a long‐acting SSRA is the inability to reduce the dose, unlike with oral preparations such as diazoxide. Given that the severity of CHI may naturally reduce over time, the use of fixed‐dose long‐acting SSRAs may be considered disproportionate.
According to DelveInsight, the Congenital Hyperinsulinism (CHI) market in 7MM is expected to witness a major change in the study period 2019–2032.
Key Companies Working in the Congenital HyperInsulinism Market
Zealand Pharma
Rezolute
Hanmi Pharmaceutical
Crinetics Pharmaceuticals
And many others
Congenital HyperInsulinism Therapies Covered and Analyzed in the Report
RZ358
HM15136
Lanreotide Autogel
Glucagon
Learn more about the Key Companies and Emerging Therapies in the Congenital HyperInsulinism Disease Market
Table of Contents
Key Insights
Congenital HyperInsulinism Disease Introduction
Executive Summary of Congenital HyperInsulinism Disease
Disease Background and Overview
Epidemiology and patient population
Congenital HyperInsulinism Disease Emerging Therapies
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @ Congenital HyperInsulinism Disease Market Outlook
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services